EFFICACY

Overall Survival rate %^a,b,c 

Image

In the BRAFTOVI + MEKTOVI arm, more than 1 in 3 patients were still alive at 5 years (35%)³

In the initial analysis (cut-off date November 2017), BRAFTOVI + MEKTOVI achieved a median OS of 33.6 months vs 16.9 months for vemurafenib (HR =0.61 [95% CI: 0.47-0.79] p<0.0001)⁴



Results at 5 years are a descriptive post hoc analysis. They should be interpreted in the context of this limitation. CI, confidence interval; HR, hazard ratio; OS, overall survival.

^aAdapted from Dummer et al. 2022³.  ^bCut-off date: September 2020. Median follow-up of 70.4 months³.  ^cOS was a secondary endpoint of the COLUMBUS study⁴.  ^dIn death³. 

ORR by central review^a,b,e,3

Cut-off date September 2020

Image

Almost 2 out of 3 patients responded to

BRAFTOVI + MEKTOVI³

ORR by local review^c,d,e,5

Cut-off date November 2018

Image

More than 3 out of 4 patients responded to

BRAFTOVI + MEKTOVI⁵

Median DoR by central review^a,b,3

Cut-off date September 2020

Image

BRAFTOVI + MEKTOVI extended the median duration

of response by more than 6 months vs vemurafenib³

In the initial analysis (cut-off date May 2016), more patients in BRAFTOVI + MEKTOVI arm attained an overall response compared with those in vemurafenib arm:

 63% (95% CI: 56– 70) vs 40% (95% CI: 33– 48) by  central review and 75% (95% CI: 68– 81) vs 49% (95% CI: 42– 57) by local review. Median duration of response was 16.6 months (95% CI 12.2– 20.4) in BRAFTOVI + MEKTOVI arm vs 12.3 months (95% CI 6.9– 16.9) in vemurafenib arm¹¹ 

Results at 5 years are a descriptive post hoc analysis. They should be interpreted in the context of this limitation. CI, confidence interval; CR, complete response; DoR, duration of response; ORR, overall response rate; PR, partial response.

^aAdapted from Dummer et al. 2022³.  ^bBy central review³.  ^cAdapted from Ascierto et al. 2020³.   ^dBy local review⁵.  ^eORR and DoR were secondary endpoints of the COLUMBUS study⁴. ^fDisease control rate = ORR (%) +  SD (%).

PFS according to baseline LDH levels^a,b 

Image

OS according to baseline LDH levels^a,b 

Image

 

Almost 4X longer median PFS in patients with

normal LDH vs high LDH with BRAFTOVI + MEKTOVI³

More than 4X longer median OS in patients with

normal LDH vs high LDH with BRAFTOVI + MEKTOVI³

OS outcomes in patients subgroups^a,b

Image

Achieve better OS outcomes across various patient subgroups³ 

Results at 5 years are a descriptive post hoc analysis. They should be interpreted in the context of this limitation. AJCC, American Joint Committee on Cancer; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LDH, lactate dehydrogenase; ULN, upper limit of normal; PFS, progression-free survival; OS, overall survival.

^aAdapted from Dummer et al. 2022³.  ^bCut-off date: September 2020³.

Time to definitive 10% deterioration in FACT-M QoL score^a,b,c

Cut-off date: November 2018

Image

 Allow patients to maintain their QoL for longer with BRAFTOVI + MEKTOVI vs vemurafenib^7,13

Change in health-related QoL from baseline over time^a,b,c

Cut-off date: November 2018

Image

BRAFTOVI + MEKTOVI brings a meaningful difference to your patients’ quality of life vs vemurafenib⁷

CI, confidence interval; EORTC QLQ, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; FACT-M, Functional Assessment of Cancer Therapy-Melanoma; HR, hazard ratio; MCID, minimal clinically important difference; MMRM, mixed model repeated measures; QoL, quality of life; SEM, standard error for the mean.

^aAdapted from Gogas et al. 2021⁷.  ^bCut-off date: November 2018⁷.  ^cQoL was a secondary endpoint of the COLUMBUS study⁷.